Proverum is an early-stage medical device company based in Dublin, Ireland. Founded in 2016 as a spin-off from Trinity College Dublin, the company is focused on developing a novel treatment solution for patients with symptomatic Benign Prostatic Hyperplasia (BPH). Their ProVee system is designed to be a safe and effective procedure that can be performed in a doctor's office under local anesthesia. By placing the device inside the urethra, it restores function and ensures normal urination, providing a non-invasive alternative to traditional treatments for BPH. Proverum has received investment from LSV in 2022 to support their pivotal trial and pursue regulatory approval for the ProVee system in Europe and the US.